In a real-world analysis involving more than 11,000 patients with atrial fibrillation from 47 countries, the risk for stroke and major bleeding in users of the direct oral anticoagulant Xarelto (rivaroxaban) was similar to or lower than that seen in the pivotal clinical trials, researchers report.